Exelixis, Inc.
EXEL
|
$22.47
-1.75%
-1.78%
2.6M
|
Health Technology
(0.0% 1d) (-1.9% 1m) (20.2% 1y) (0.0% 2d) (2.1% 3d) (0.9% 7d) (NaN% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 6,812,775,000
http://www.exelixis.com
Sec Filling | Patents | 617 employees
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
cancer brands treatment
Drugs
CABOMETYX (cabozantinib)COMETRIQ (cabozantinib)
add to watch list Paper trade email alert is off
Press-releases
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
first financial results
Acadia Announces Additions to Executive Team - Jan 31, 2024
Published: 2024-01-31 (Crawled : 10:00) - biospace.com/
INBX | $34.47 -0.41% -0.41% 420K
|
Health Technology
|
| O: -0.36%
H: 0.57%
C: -0.21%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.18%
H: 0.55%
C: -0.78%
ACAD | News | $17.08 -0.64% -0.64% 990K
|
Health Technology
|
| O: -0.71%
H: 0.71%
C: -2.74%
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
Published: 2024-01-18 (Crawled : 00:00) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.89%
cabometyx patent
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
Published: 2024-01-12 (Crawled : 11:00) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.8%
H: 1.66%
C: 0.49%
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
Published: 2024-01-08 (Crawled : 12:30) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.07%
H: 0.48%
C: 0.48%
SITE | $158.26 -1.51% 0.0% 230K
|
Distribution Services
|
| O: -1.03%
H: 2.25%
C: 2.16%
XOMA | News | $24.96 2.93% 2.84% 15K
|
Health Technology
|
| O: 0.43%
H: 4.52%
C: 4.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -12.39%
H: 10.85%
C: 10.71%
jack
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Published: 2024-01-02 (Crawled : 23:00) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.42%
H: 1.88%
C: 0.17%
conference
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.46%
H: 2.75%
C: 2.7%
ellar-305 cancer trial
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
Published: 2023-11-21 (Crawled : 00:00) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.67%
H: 3.15%
C: 2.07%
conference
Halia Therapeutics Appoints Former Amgen Scientists, Lisa Shamon, Ph.D., as Vice President of Regulatory Affairs and Xianne Leong Penny, Ph.D., as Senior Medical Director
Published: 2023-11-16 (Crawled : 13:00) - prnewswire.com
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.28%
H: 0.54%
C: -0.9%
medical therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
SNDA P 3000 | $29.61 3.35% 0.0% 30K
|
n/a
|
22:00
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M
|
Distribution Services
|
20:00
QCRH | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K
|
Health Technology
|
18:00
VUZI | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K
|
Miscellaneous
|
15:00
RELL | $10.15 2.94% 2.86% 94K
|
Electronic Technology
|
13:30
IZEA | $2.65 4.74% 4.53% 31K
|
Technology Services
|
00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M
|
Finance
|
22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M
|
Health Technology
|
16:30
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10